A truly effective cystic fibrosis (CF) disease modifying therapy needs to decrease the rate of lung function decline and improve both quality of life as well as life expectancy. The introduction and exceptional success of the CFTR protein potentiator ivacaftor began an exciting new era of progress in treating not just the symptoms of CF, but also the actual underlying mechanisms of the disease itself.
In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health and Dr. Shijing Jia from the University of Michigan analyze the current literature describing the newest frontiers of CF therapy.
Associate Professor
Co-Director/CF TDN Director, Adult CF Program
Departments of Internal Medicine and Pediatrics
Pulmonary Division
National Jewish Health
Denver, CO
Assistant Professor
Department of Pulmonology
Michigan Medicine Pulmonary Clinic – Taubman Center
Ann Arbor, MI
Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD
Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: August 30, 2019
Expiration date: August 29, 2021